Tryptamine Therapeutics Limited (ASX:TYP)

Market Cap	43.20M
Revenue (ttm)	1.58M
Net Income (ttm)	-5.33M
Shares Out	1.44B
EPS (ttm)	-0.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	3,332,868
Average Volume	1,670,439
Open	0.0330
Previous Close	0.0320
Day's Range	0.0300 - 0.0330
52-Week Range	0.0170 - 0.0570
Beta	n/a
RSI	43.48
Earnings Date	Sep 30, 2025

About Tryptamine Therapeutics

Tryptamine Therapeutics Limited, a clinical-stage pharmaceutical development company, focuses on developing formulations for the administration of psilocin in combination with psychotherapy to treat diseases with unmet medical needs in Australia, Canada, Switzerland, and the United States. The company’s lead program candidate is TRP-8803, a formulation of IV-infused psilocin that completed Phase 2 clinical trial for the treatment of binge eating disorder, fibromyalgia, irritable bowel syndrome, abdominal pain, and visceral tenderness. It is als...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2019
• Country: Australia
• Stock Exchange: Australian Securities Exchange
• Ticker Symbol: TYP

Financial Performance

In 2025, Tryptamine Therapeutics's revenue was 1.58 million, an increase of 19.17% compared to the previous year's 1.33 million. Losses were -5.33 million, -27.66% less than in 2024.